FDA Approves MARGENZA
On December 16, 2020, the FDA approved margetuximab-cmkb (MARGENZA®, MacroGenics) in combination with chemotherapy, for the treatment of patients with metastatic...
Read MoreTreating Breast Cancer Brain Mets
Treatment options for breast cancer brain metastases (BCBM) have historically included only surgery, radiation, and limited clinical trial access. However, due to...
Read MoreWhat You Need to Know About Washout Periods
In clinical trials, a washout period describes the length of time that someone enrolled in a trial must not receive any treatment before receiving the trial’s...
Read MoreSpotlight on MBC Podcasts
Listening to podcasts can help you feel connected to your communities, especially during the social isolation of the current pandemic. This month we highlight two...
Read MoreWhat is Next-Generation Sequencing?
Next-generation sequencing (NGS) is not the name of a specific breast cancer test. Instead, it is a category of tests that look for all the genomic mutations in a...
Read MoreLines of Therapy: New Drugs May Change MBC Treatment
Which therapy to use for the first, second or third line of treatment for metastatic breast cancer is again under investigation because new therapies have become...
Read MoreWhat Are Lines of Therapy and What You Need to Know
“Lines of therapy” is the term used to describe the order in which different therapies are given to people as their disease progresses. In practice, doctors may...
Read MoreWarmest Wishes for 2021
As our community knows, the COVID-19 pandemic greatly affected all aspects of breast cancer care, including clinical trials. Yet, with your support, we have been...
Read MoreWhen to Use Surgery & Radiation to the Breast
Headlines announcing the phase III clinical trial (ECOG-ACRIN 2108) results stated that radiation and surgery to the breast–also called locoregional therapy...
Read MoreSEARCH OUR SITE
for past articles or specific information.